Please ensure Javascript is enabled for purposes of website accessibility

Is Now the Time to Go All-In On Novavax Stock?

By Zhiyuan Sun - Jun 20, 2021 at 6:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This coronavirus vaccine developer is near the finish line to the already-decided vaccine race.

On June 14, Novavax (NVAX 2.00%) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups.

Unfortunately, shareholders have been acting in a "buy the rumor, sell the news" sort of manner. Shares fell about 10% after Novavax published the results. As of now, the company is pretty undervalued relative to its vaccine production capacity and potential commercialization. Should investors put all their eggs in one basket for this stock? 

Patient receiving a vaccine from a doctor.

Image source: Getty Images.

What are the odds? 

Based on the results, Novavax plans to file for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in the next quarter for NVX-CoV2373. By the end of the year, the company plans to produce 150 million vaccine doses each month. The company already has advance purchase agreements for 310 million doses with various developed nations. It also finalized a 350 million-dose supply agreement to international vaccine alliance Gavi via its contract manufacturer Serum Institute of India.

The opportunity for Novavax to partake in vaccination campaigns in G7 countries is mostly over. However, the company stands to play a significant role in delivering billions of doses of vaccines to middle- and low-income countries. That's not to mention the potential to supply booster shots as antibody levels decrease over time. Novavax is ready to deploy NVX-CoV2373, having secured over $2 billion in funding since the beginning of the pandemic for this purpose.

But the biggest risk facing long-term investors is sustainability. I do not doubt that Novavax could make billions (or even tens of billions) in revenue by commercializing NVX-CoV2373 next year. But I just can't see Novavax still supplying billions of doses of vaccines in 2025. 

What happens when coronavirus vaccine sales fall off a cliff? The company's mRNA vaccine peers, like Moderna (MRNA 3.27%) and BioNTech (BNTX 1.33%), already have that figured out. Both companies are heavily reinvesting their vaccine cash flows into mRNA cancer vaccines. Since this technology involves injecting mRNA-encoded genetic instructions into a patient's body regarding mutations (such as from a tumor sample), it is theoretically scalable across a large variety of diseases.

Unfortunately, Novavax has taken a different approach to research and development. It is historically known for developing influenza vaccines, which typically have low or moderate efficacy. Given the very low fatality rate for that disease, many people tend to skip out on flu shots even when health authorities recommend them.

The verdict? 

At this point, Novavax does not have the problem of sustaining its (upcoming) revenue and earnings figured out. Investors should keep in mind that the high likelihood of success for NVX-CoV2373 is largely priced into the stock. I would definitely not go all-in just because the vaccine candidate is highly efficacious. It's best to wait until the biotech has more promising candidates in its pipeline before initiating a stake. 

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$42.30 (2.00%) $0.83
Moderna, Inc. Stock Quote
Moderna, Inc.
$176.78 (3.27%) $5.60
BioNTech SE Stock Quote
BioNTech SE
$162.48 (1.33%) $2.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.